Prospective cohort study identifies risk factors for gout flares in adults receiving urate-lowering treatment, suggesting clinical implications.
Background: Gout is an inflammatory arthritis caused by the monosodium urate crystal deposition in joints, with some patients experiencing recurrent flares.This study compared the clinical characteristics of patients who experienced gout flares with those who did not.Methods: Data were analyzed from the Urate Lowering TheRApy in Gout registry, including adults aged ≥ 18 years who met the 2015 American College of Rheumatology/European League Against Rheumatism gout classification criteria.Patients were designated into flare or no-flare groups based on the occurrence of at least one gout flare within the first 6 months.Results: Among 327 patients, 29.0% experienced at least one gout flare within 6 months.Compared with the no-flare group, patients with flares had higher gout impact scale (P = 0.019) and EuroQoL 5-Dimension 3-Level scores (P = 0.012), and more frequent bone erosion (P < 0.001), and tophi (P = 0.031).Multivariate logistic regression showed that radiographic bone erosion (P = 0.013) and poorer quality of life (gout impact scale, P = 0.037; EuroQoL 5-Dimension 3-Level scores, P = 0.014) were independently associated with
No takes yet. Share an insight, caveat, or question.
Do et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: